The UAE’s blueprint for living healthier for longer

Across the Gulf Cooperation Council (GCC), healthcare systems are shifting from reactive treatment models to proactive health optimisation. The United Arab Emirates (UAE) is at the forefront of this change, establishing comprehensive longevity ecosystems ─ integrated frameworks in which regulation, genomics, and digital infrastructure converge to extend healthspan, not just lifespan. The goal is to shift the focus from simply living a long time to maintaining high physical, cognitive, and social functioning throughout those years.

Unlike models in many Western countries focused on ageing populations, the UAE’s approach is tailored for its younger, health-conscious residents seeking early intervention, preventive care, and sustained performance.

The UAE faces what has been termed the 'GCC health paradox', a youthful population with chronic diseases emerging significantly earlier than global averages. While the median age remains below 35, lifestyle-related conditions appear 10-15 years sooner than in other developed nations. Diabetes affects over one-fifth of adults (20.7% prevalence), while obesity exceeds 31%. National cohort studies confirm that cardiometabolic risk factors, such as hypertension and insulin resistance, are increasingly common in adults in their 30s. This creates a dual challenge: managing these early-onset conditions while simultaneously preparing for the future healthcare needs of an ageing population, underscoring the need for early screening, behavioral interventions, and longitudinal risk tracking.

The longevity ecosystem operates across five interconnected domains that drive innovation, service delivery, and commercial growth. These domains, designed to promote long-term health, reflect the sectors’ transition from a niche clinical concept to a broader healthcare and economic opportunity.

In the UAE, the longevity economy is underpinned by strong policy alignment and strategic investment in science and digital health. The National Strategy for Wellbeing 2031, with its strong focus on preventive health, together with the National Genome Strategy, the Emirati Genome Program and the Longevity Ambassadors Program, has elevated healthy ageing to a national priority, creating an integrated approach aligned with the UAE Centennial 2071. In parallel, Abu Dhabi’s life sciences expansion under the HELM (Health, Endurance, Longevity and Medicine) cluster, alongside the Sharjah Research Technology and Innovation Park (SRTIP) and Deep Knowledge Analytics (DKA) collaboration to map out the UAE's longevity industry, reflects a broader push to connect biotechnology, research, and commercialisation within the longevity landscape.

A pivotal moment for the UAE arrived in 2024, when Abu Dhabi’s Department of Health (DoH) launched its Healthy Longevity Medicine Centre (HLMC) Licensing Framework, a pioneering regulatory framework dedicated to longevity medicine as a clinical specialty focused on preventive, predictive, and regenerative care. The Institute for Healthier Living Abu Dhabi (IHLAD) became the first facility licensed under this model, positioning Abu Dhabi as a global benchmark for regulated longevity medicine.

IHLAD now serves as the institutional anchor for a rapidly growing commercial ecosystem. It is complemented by a range of specialised providers delivering different aspects of longevity care.

In Abu Dhabi, Pura Longevity Clinic, operated by PureHealth at Sheikh Shakhbout Medical City (SSMC), delivers AI-enabled diagnostics and structured preventive care. The Abu Dhabi Stem Cells Centre (ADSCC) is recognised as a Centre of Excellence in haematopoietic stem cell transplantation and advanced cellular therapies. Meanwhile, Dubai offers the luxury medical-wellness experience at Clinique La Prairie's Longevity Hub.

Other centres, such as Elite Vita and AEON Clinic in Dubai, focus on regenerative therapies and personalised health optimisation. At the same time, ambitious projects like SHA Wellness Island underscore the scale of investment in the sector.

Supporting this clinical ecosystem is a powerful digital infrastructure. The UAE’s three major health information systems — Riayati, Malaffi, and NABIDH — integrate data from over 1.9 billion health records for 9.5 million patients across more than 3,000 healthcare facilities, enabling predictive analytics, interoperability, and longitudinal care tracking.

Across the region, other nations are making strides in health innovation. Saudi Arabia is investing in longevity science, with the Hevolution Foundation allocating a planned $115 million budget over five years starting in 2024 for international geroscience research, while King Abdullah University of Science and Technology (KAUST) advances research in biotechnology, genomics, and personalised medicine. Meanwhile, Qatar’s Genome Program is embedding precision health into its public system, and the Qatar Biomedical Research Institute (QBRI) is actively engaged in research on aging and age-related diseases, focusing on genomics, precision medicine, and regenerative medicine.

As its neighbors concentrate on research, the UAE’s distinct advantage lies in implementation. By skillfully integrating regulation, genomics, and technology into a functional, day-to-day healthcare model, the UAE has set a practical standard. This focus places it alongside global frontrunners like Singapore and Switzerland in making healthspan-focused medicine a reality.

The longevity market in the UAE, while promising, remains in its early stages and faces several key hurdles. A primary challenge is the development of a specialised talent pipeline with expertise in geroscience, preventive medicine, and data analytics; while momentum is being built, formalised educational pathways and integrated healthcare practice models are still evolving.

Reimbursement remains another barrier, as a significant share of longevity services continue to operate on an out-of-pocket basis, limiting broader adoption. Financial frameworks must evolve, yet insurance providers require long-term data to prove the efficacy and cost savings of preventive services. Furthermore, as the integration of sensitive health data deepens, protecting patient privacy will be a priority. As the market expands beyond niche providers, maintaining consistency in clinical quality and differentiating evidence-based care from commercially driven services will also be essential.

While the longevity market initially expanded through premium, wellness-driven formats within the private healthcare sector, there is an increasing movement toward more clinically structured preventive models and biological age diagnostics. However, a significant share of the market continues to operate within high-margin wellness and aesthetic segments. This reflects the broader global trend in which evidence-based longevity medicine and commercially driven "biohacking" or wellness services coexist within the same ecosystem. The extent of wider implementation and clinical integration will determine whether longevity matures into a core healthcare discipline rather than remaining concentrated within a high-margin niche. For longer sustenance, the market will require a definitive shift toward evidence-based care.

As this sector expands, the demand for specialised infrastructure also grows, ranging from advanced longevity clinics and research facilities to wellness-integrated communities. For expert guidance in this evolving field, JLL Healthcare offers strategic consulting services, market strategy, and growth advisory. Visit JLL Healthcare to learn how we can help you navigate the opportunities in this dynamic market.